Educational questions for patients · United StatesUrgent contacts →
GLP-1
Safety Guide

Evidence index

Go to the
original guidance.

Original research October 5, provider reviews October 15, and scientific sources October 21, 2026. Open current guidance when a question arises.

Sources and limits

Scientific sources checked October 21, 2026. Earlier research and provider sources retain their dated histories below. Federal sources provide general guidance; provider pages describe advertised terms. These sources do not assess an individual patient's situation.

  1. MedlinePlus — tirzepatide injection precautionsFederal patient drug information
  2. HRSA Poison Help — calling for expert guidanceFederal poison-response resource
  3. HRSA Poison Help — what you can doFederal emergency preparedness guidance
  4. FDA BeSafeRx — online pharmacy informationPharmacy verification and reporting resources
  5. CoreAge Rx — official treatment pagesProvider offer
  6. CoreAge Rx — tirzepatide offerProvider offer
  7. CoreAge Rx Help Center — Pricing & PlansProvider billing terms
  8. SuperHealthy Rx — current GLP-1 offerProvider offer
  9. Likeness Rx — GLP-1 plans and billingProvider offer
  10. Ro Body — membership and medication costsProvider offer
  11. WeightWatchers — Med+ membership and medicationProvider offer
  12. LillyDirect — pharmacy access and independent care optionsManufacturer access program
  13. FDA — concerns with unapproved GLP-1 drugsRegulator guidance
  14. FDA — compounding questions and answersRegulator guidance
  15. FDA — dosing errors with compounded injectable semaglutideSafety alert, July 2024
  16. NIDDK — prescription medications for overweight and obesityFederal patient education
  17. BeSafeRx: Frequently Asked Questions (FAQs)Primary health resource; checked October 5, 2026
  18. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossPrimary health resource; checked October 5, 2026
  19. It can be a lifesaving tool, especially during an emergencyPrimary health resource; checked October 5, 2026
  20. What Should I Ask My Doctor During a Checkup?Primary health resource; checked October 5, 2026
  21. Medical Weight Loss Programs Available OnlineProvider public offer; checked October 5, 2026
  22. How It Works - PlushCareProvider public offer; checked October 5, 2026
  23. Online weight loss medication with or without insuranceProvider public offer; checked October 5, 2026
  24. Telehealth for Weight Loss, Hair Loss, Skin & More | Mochi HealthProvider public offer; checked October 5, 2026
  25. Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
  26. Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
  27. SlimShot: Current medical weight-management homepageProvider public information; checked October 15, 2026
  28. SlimShot: Separate public WL Meds order pageProvider public information; checked October 15, 2026
  29. SlimShot: Main-site terms of serviceProvider public information; checked October 15, 2026
  30. WL Meds: Terms linked from the SlimShot order page; November 22, 2023 PDFProvider public information; checked October 15, 2026
  31. Unique Physique: Public GLP-1 consultation pageProvider public information; checked October 15, 2026
  32. Unique Physique: Program prices and state exclusionsProvider public information; checked October 15, 2026
  33. Unique Physique: Consultation, renewal and cancellation policiesProvider public information; checked October 15, 2026
  34. Unique Physique: General terms and conditionsProvider public information; checked October 15, 2026
  35. Unique Physique: Operator and privacy informationProvider public information; checked October 15, 2026
  36. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Full primary post hoc analysis main text and main Table 1 reviewed; supplementary file and original trial protocols not independently reviewed. · Checked 2026-10-21
  37. Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.Full primary post hoc report, Methods, Results, main Table 1 and Discussion/funding reviewed; supplementary tables and source-trial protocols not separately reviewed. · Checked 2026-10-21
  38. DailyMed: WEGOVY semaglutide current prescribing informationCurrent official DailyMed label, updated June 18, 2026, current archive June 30, 2026; indications, relevant safety sections 5.2, 5.3, 5.5, 5.6, 5.10, postmarketing experience and oral-drug interaction sections reviewed. Other sections not fully reviewed. · Checked 2026-10-21
  39. DailyMed: ZEPBOUND tirzepatide current prescribing informationCurrent official DailyMed label, updated August 28, 2026, current archive September 2, 2026; indications, relevant safety sections 5.2 through 5.5 and 5.9, postmarketing experience and oral-drug interaction sections reviewed. Other sections not fully reviewed. · Checked 2026-10-21